| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (replaced TA205) |
|
Medicine details |
|
| Medicine name | eltrombopag (Revolade®) |
| Formulation | film-coated tablet |
| Reference number | 121 |
| Indication | Treatment of adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Eltrombopag may be considered as second line treatment for adult non-splenectomised patients where surgery is contraindicated |
| Company | GlaxoSmithKline |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/02/2010 |
| NICE guidance | |